GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alvotech (NAS:ALVOW) » Definitions » Insider Ownership

Alvotech (Alvotech) Insider Ownership : 0.00 % (As of Jun. 08, 2024)


View and export this data going back to 2022. Start your Free Trial

What is Alvotech Insider Ownership?

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Alvotech's insider ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Alvotech's Institutional Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Alvotech's Float Percentage Of Total Shares Outstanding is N/A.


Alvotech Insider Ownership Historical Data

The historical data trend for Alvotech's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alvotech Insider Ownership Chart

Alvotech Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Insider Ownership
- - - - -

Alvotech Quarterly Data
Dec19 Dec20 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Insider Ownership Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Alvotech Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.


Alvotech (Alvotech) Business Description

Traded in Other Exchanges
Address
9, rue de Bitbourg, Luxembourg, LUX, L-1273
Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. its purpose is to improve the health and quality of life of patients around the world by improving access to proven treatments for various diseases.